Norway· NO-ID_0E2B5239-4B55-4285-8B7A-5705B953F6FE
Lariam
A mefloquine product containing mefloquine hydrochloride, registered in Norway by Cheplapharm Arzneimittel GmbH. The same ATC class is registered in 9 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Mefloquine is registered in 9 of 19 countries.
Countries holding a registration under ATC P01BC02 (mefloquine), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 5 of them publish a price we can compare per daily dose
Mefloquine · ATC P01BC02
9 / 19 countries
- Belgiumprice
- Canada
- Finlandprice
- Japan
- Netherlands
- Norwayprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FEST (Norway)- Active substance
- Mefloquine Hydrochloride
- Manufacturer
- Cheplapharm Arzneimittel GmbH
- Country
- Norway (NO)
- ATC code
- P01BC02
- ATC class
- Mefloquine
- Defined daily dose
- 1 g, O
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 3
1 priced- no_merkevare_idID_0E2B5239-4B55-4285-8B7A-5705B953F6FE
- no_varenummer0058848NOK 284.9
- gtin4260095681911
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
439 interactions on record for mefloquine.
Graded by severity as the source publishes them — 82 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Mefloquine · interactions on record
439 records
- 82 severe
- 338 moderate
- 8 minor
- 11 info
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- DolasetronA04AA04severe
- ProcainamideC01BA02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Mefloquine in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NetherlandsLariam 250 mg, tablettenMedcor Pharmaceuticals B.V.
- United KingdomLariam 250mg tabletsSigma Pharmaceuticals Plc
- United StatesMefloquine HydrochlorideA-S Medication Solutions
- FinlandLariamParanova Oy
- FranceLARIAM 250 mg, comprimé sécableCHEPLAPHARM ARZNEIMITTEL (ALLEMAGNE)
- CanadaMEFLOQUINEAA PHARMA INC
- SwedenLariam 250 mg TablettCheplapharm Arzneimittel GmbH
- SwitzerlandMephaquin, FilmtablettenMepha Pharma AG
Authorised across Europe · EMA
The same active substance is authorised in 11 EEA countries. Names it is sold under:
- Austria · Lariam
- Belgium · Lariam
- Cyprus · Eloquine
- Finland · Lariam
- France · Lariam
- United Kingdom (Northern Ireland) · Lariam, Mefloquine
- Italy · Lariam
- Luxembourg · Lariam
- Netherlands · Lariam
- Portugal · Mephaquin Lactab
- Sweden · Lariam
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/253d21f2-bf60-4ecb-bcb6-f1dc7de5aa25 GET /v1/drugs/253d21f2-bf60-4ecb-bcb6-f1dc7de5aa25?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tablett",
"source": "fest",
"status": "A",
"atc_name": "Meflokin",
"merkevare_id": "ID_0E2B5239-4B55-4285-8B7A-5705B953F6FE",
"name_form_strength": "Lariam tab 250 mg",
"prescription_group": "C"
}See everything about mefloquine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.